Terapia Intensiva

In our latest paper from ISARIC4C we show that covid and flu together is a dangerous combination: 4x greater odds of needing a ventilator; 2x greater odds of dying. So we should test more widely for flu, and if you are offered a vaccine, please take it https://t.co/gI2GQnTRQH

— Kenneth Baillie (@kennethbaillie) March 25, 2022

Há evidência de dados fabricados em um estudo sobre vitamina C publicado na revista CHEST?

29 Mar, 2022 | 14:17h

Evidence of Fabricated Data in a Vitamin C trial by Paul E Marik et al in CHEST – This Scattrd Corn

Comentário: Infamous Vitamin C Study May Rely on Fraudulent Data— Statistician alleges data in study led by Paul Marik, MD, were fabricated – MedPage Today

Comentário no Twitter (fio – clique para saber mais)

Remember that Vitamin C cures sepsis paper that could never be replicated in 9 RCTs?

Turns out there is a good reason why: it’s very likely fraudulent.

More brilliant statistical sleuthing by @K_Sheldrick.https://t.co/eCayYZyeGo
1/

— Nick Mark MD (@nickmmark) March 22, 2022

Estudo randomizado | Em pacientes imunocomprometidos críticos com insuficiência respiratória aguda, os desfechos foram similares com o uso de oxigênio nasal de alto fluxo vs. alternância com ventilação não invasiva.

29 Mar, 2022 | 14:02h

High-flow nasal oxygen alone or alternating with non-invasive ventilation in critically ill immunocompromised patients with acute respiratory failure: a randomised controlled trial – The Lancet Respiratory Medicine (necessário cadastro gratuito)

Comentário no Twitter

NEW Research—In critically ill immunocompromised patients with acute respiratory failure, the mortality rate did not differ between HFNO alone and NIV alternating with HFNO

FLORALI-IM study from Rémi Coudroy & co https://t.co/xSJfQ9yTCt

Presented today at @ISICEM #ISICEM2022 pic.twitter.com/ooHnRcVnFV

— The Lancet Respiratory Medicine (@LancetRespirMed) March 22, 2022

M-A | Mortalidade da bacteriemia por Staphylococcus aureus.

25 Mar, 2022 | 15:31h

Staphylococcus aureus bacteremia mortality: A systematic review and meta-analysis – Clinical Microbiology and Infection

Estudo randomizado | Tratamento com dose única de anfotericina B lipossomal para meningite por criptococo.

25 Mar, 2022 | 15:01h

Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário no Twitter

Cryptococcal meningitis is a major complication of HIV infection. Single-dose liposomal amphotericin B combined with flucytosine and fluconazole was noninferior to the WHO-recommended treatment and was associated with fewer adverse events. https://t.co/cg9DqSDhyN pic.twitter.com/SrKx4tDaph

— NEJM (@NEJM) March 23, 2022

Estudo randomizado | Posição prona em pacientes não intubados não melhorou os desfechos em pacientes com hipoxemia moderada relacionada à Covid-19.

25 Mar, 2022 | 14:58h

Prone positioning of patients with moderate hypoxaemia due to covid-19: multicentre pragmatic randomised trial (COVID-PRONE) – The BMJ

Editorial: Awake prone positioning for patients with covid-19

Comunicado de imprensa: Lying prone long enough to improve outcomes is difficult for many covid-19 patients – BMJ

Estudo randomizado | Entre pacientes críticos com Covid-19, o tratamento com um agente antiplaquetário teve pouca propensão a melhorar os dias sem suporte de órgão em 21 dias.

24 Mar, 2022 | 12:33h

Effect of Antiplatelet Therapy on Survival and Organ Support–Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial – JAMA

Editorial: Thromboinflammation and Antithrombotics in COVID-19: Accumulating Evidence and Current Status – JAMA

Comentário: Aspirin may improve 3-month survival for patients critically ill with COVID-19 – Imperial College London

Comentários no Twitter

In this bayesian randomized clinical trial, among critically ill patients with #COVID19, there was a low likelihood that treatment with an antiplatelet agent provided improvement in organ support–free days within 21 days. https://t.co/CnyWoOTn3Q

— JAMA (@JAMA_current) March 22, 2022

Revisão | Quando operar após infecção por SARS-CoV-2?

23 Mar, 2022 | 12:02h

When to operate after SARS-CoV-2 infection? A review on the recent consensus recommendation of the DGC/BDC and the DGAI/BDA – Langenbeck’s Archives of Surgery

Conteúdos relacionados:

Guideline Update: Timing of elective surgery and risk assessment after SARS-CoV-2 infection – “The guidance remains that patients should avoid elective surgery within 7 weeks of infection, unless the benefits of doing so exceed the risk of waiting”.

Perioperative cardiovascular considerations prior to elective noncardiac surgery in patients with a history of Covid-19.

Guideline: SARS‐CoV‐2 infection, COVID‐19 and timing of elective surgery

Study from 116 countries suggests surgery should be delayed for at least seven weeks following a COVID-19 diagnosis to reduce mortality risk

BJS commission on surgery and perioperative care post-COVID-19.

The risk of postoperative complications following major elective surgery in active or resolved COVID-19 in the United States – Major, elective surgery 0–4 weeks after Covid-19 is associated with greatly increased risk of postoperative complications; surgery performed 4–8 weeks after infection is still associated with an increased risk of pneumonia.

ASA Guidance: Preoperative testing for COVID-19 is essential, regardless of vaccination.

Position statement: Perioperative management of post-COVID-19 surgical patients.

Cohort study: Postoperative in-hospital mortality of patients with COVID-19 infection was more than double that in patients without COVID-19

Revisão | Diagnóstico e tratamento neurointervencionista do AVC isquêmico por oclusão de grandes vasos.

Série de revisões | Artigos selecionados do Annual Update in Intensive Care and Emergency Medicine 2022.

Estudo de coorte | Coinfecção SARS-CoV-2 e influenza, vírus sincicial respiratório ou adenovírus está associada com mortalidade aumentada.